DEEP RESEARCH · VORONOI

Voronoi: VORONOMICS and the VRN11/VRN10 Global Leap Thesis

A review of precision targeted therapy, BBB penetration, and 2026 clinical/licensing catalysts.

Date: 2026-01-16 · precision oncology/kinase-inhibitor lens · Naver Blog original

0. Bottom line first

Official fact: The source presents a Buy opinion, KRW 300,000 target price, and about 46% upside. This is the source author's research opinion, not a recommendation here.

Interpretation: The main checkpoints for me are VRN11's C797S and first-line expansion, VRN10's potential as an Enhertu combination partner, and the clinical data expected through 2026.

1. Company and VORONOMICS platform

Official fact: Voronoi was founded in February 2015 and has its headquarters and key research facilities in Songdo, Incheon. It also operates VORONOI USA, INC., a 100%-owned Boston subsidiary, for global clinical and business-development work.

Official fact: As of Q3 2025, Voronoi had 149 employees. The source highlights a connected R&D infrastructure across medicinal chemistry, biology, animal testing, and AI labs, and says the company shortened candidate discovery from a typical 4.5 years to 1-1.5 years.

• Selectivity: the platform aims to reduce toxicity by targeting specific kinases among more than 500 human kinases.
• BBB penetration: from the molecular-design stage, properties favorable to brain penetration are optimized for brain-metastasis challenges in lung and breast cancer.
• Validation: VRN07/ORIC-114 was licensed to ORIC Pharmaceuticals in October 2020, and VRN06 was licensed to HK inno.N in 2021.

2. Market setup

Interpretation: The competition in kinase inhibitors is shifting from efficacy alone to selectivity, toxicity, and BBB penetration. The source treats Tagrisso-resistant C797S and HER2 ADC combination limits as Voronoi's opportunity.

3. VRN11: fourth-generation EGFR TKI

Official fact: VRN11 is a fourth-generation TKI that selectively binds EGFR mutations including C797S. C797S is a resistance mechanism in which Cysteine 797, the covalent binding site for Tagrisso, changes to Serine and interferes with drug binding.

The source also says a complete response in brain metastasis was reported in a 160mg cohort. It frames the C797S mutation market at about KRW 1tn and the first-line market at KRW 15tn in annual revenue, arguing that the strategy extends from second-line use into first-line treatment.

4. VRN10: Enhertu combination-partner thesis

VRN10 is presented as a small-molecule TKI candidate that could complement Enhertu's strong HER2-positive breast-cancer efficacy while addressing the combination limits created by ILD and liver-toxicity concerns.

Official fact: The source says recent phase 1a data showed tumor-size reduction with VRN10 monotherapy and no liver toxicity, which is a chronic issue for competing drugs.

Interpretation: The key is that VRN10 promotes HER2 receptor internalization. Since ADCs need to bind receptors and enter cells to release payloads, the source argues VRN10 could help Enhertu deliver more anticancer effect in combination.

5. Pipeline and financials

6. 2026 catalysts and risks

• First half 2026: VRN11 global phase 1b/2 study entry in treatment-naive patients.
• Second half 2026: VRN11 first-line efficacy data and Depth of Response versus Tagrisso.
• Ad hoc event: possible global licensing deal for VRN10.
• Risks: clinical failure, weak data quality, dilution from financing, CB/EB overhang, and delay of a large L/O deal.

7. My conclusion

For Voronoi, 2026 data may decide the direction of enterprise value. VRN11 combines a C797S opportunity with first-line expansion potential, while VRN10 has strategic positioning as an Enhertu-combination candidate. Still, all valuation logic in the source depends on clinical data and licensing execution, so data quality should come before headline numbers.